Form 4: Aadi Bioscience Chief Medical Officer Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Loretta M. Itri, Chief Medical Officer of Aadi Bioscience, Inc., reports the acquisition of stock options and restricted stock units as part of her compensation.
Summary
- Loretta M. Itri, the Chief Medical Officer of Aadi Bioscience, Inc., filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
- On March 1, 2024, Itri acquired 76,813 stock options with a strike price of $1.92, fully vested immediately as part of her 2023 bonus.
- She also acquired 60,000 stock options with a strike price of $1.92, vesting over four years from March 1, 2024.
- Additionally, Itri received 30,000 restricted stock units (RSUs), vesting over four years from March 1, 2024.
- All grants are contingent upon her continued service as a Service Provider as defined in the Issuer's 2021 Equity Incentive Plan.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating a stable and ongoing operation. The sentiment is neutral to positive as it suggests continued commitment from a key executive.
Positives
- The grant of stock options and RSUs aligns the Chief Medical Officer's interests with those of the shareholders.
- The vesting schedule for a portion of the options and RSUs incentivizes continued service with the company.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option and RSU grants are common compensation practices for executives in the biotechnology industry, aligning their interests with shareholders and incentivizing long-term performance.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Vesting schedules, such as the four-year vesting period described, are typical to ensure long-term commitment.
- The specific number of options and RSUs granted would be benchmarked against peer companies of similar size and stage of development.
Stakeholder Impact
- Shareholders: The grants align executive interests with shareholder value.
- Employees: The grants may have a positive impact on employee morale by demonstrating investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of earliest transaction, grant date for stock options and RSUs, and vesting commencement date. |
| 03/01/2034 | Expiration date for the stock options. |
| 03/04/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.